➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
Dow
McKinsey
Boehringer Ingelheim
Harvard Business School

Last Updated: September 19, 2020

DrugPatentWatch Database Preview

Details for Patent: 10,080,733

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 10,080,733 protect, and when does it expire?

Patent 10,080,733 protects VUMERITY and is included in one NDA.

This patent has forty-six patent family members in twenty-five countries.

Summary for Patent: 10,080,733
Title:Prodrugs of fumarates and their use in treating various diseases
Abstract: The present invention provides compounds of formula (I), and pharmaceutical compositions thereof. ##STR00001##
Inventor(s): Zeidan; Tarek A. (Lexington, MA), Duncan; Scott (Bedford, MA), Hencken; Christopher P. (Boston, MA), Wynn; Thomas Andrew (Lexington, MA), Sanrame; Carlos N. (Lexington, MA)
Assignee: Alkermes Pharma Ireland Limited (Dublin, IE)
Application Number:15/782,128
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;

Drugs Protected by US Patent 10,080,733

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Biogen VUMERITY diroximel fumarate CAPSULE, DELAYED RELEASE;ORAL 211855-001 Oct 29, 2019 RX Yes Yes   Start Trial   Start Trial Y Y METHOD OF TREATING MULTIPLE SCLEROSIS   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,080,733

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2014239641   Start Trial
Australia 2016222363   Start Trial
Australia 2018200497   Start Trial
Brazil 112015022854   Start Trial
Canada 2906580   Start Trial
Canada 2992211   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Medtronic
Boehringer Ingelheim
McKesson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.